Hemophilia gene therapy—New country initiatives

• Published in: Haemophilia : the official journal of the World Federation of Hemophilia 2021-02, Vol.27 (S3), p.132-141
• Main Authors: Reiss, Ulrike M., Zhang, Lei, Ohmori, Tsukasa
• Format: Article
• Language: English
• Subjects: China; Clinical trials; Coagulation factors; Factor IX deficiency; FIX gene; Gene therapy; global; haemophilia; Hemophilia; Japan; low‐and middle‐income country
• ISSN: 1351-8216; 1365-2516
• DOI: 10.1111/hae.14080

Gene therapy is an opportunity for haemophilia patients to receive a one‐time treatment and have lasting factor levels for years or decades instead of dependence on repeated administration within short intervals and on sustained supply of drug. Great strides have been made in the development of gene therapy for haemophilia in the last decade. Adeno‐associated virus (AAV) vector–mediated gene transfer in haemophilia A and B has entered the phase III trial stage. Gene transfer by lentiviral vector or gene editing technologies using factor VIII (FVIII) or IX (FIX) genes are now entering clinical evaluation. It is expected that the first FVIII and FIX gene therapy products will soon be approved and distributed in major markets. Global access to gene therapy is a critical goal. This review presents new and ongoing efforts towards this goal in countries other than North America and Europe. In Japan, researchers, regulators and funders have established a promising gene therapy development platform for multiple diseases including haemophilia. Decades of scientific and clinical research in haemophilia gene therapy in China have led to a recently registered clinical trial of AAV‐mediated gene therapy for haemophilia B. Other countries are in earlier phases of building gene therapy programmes or participate in international trials. A phase 2 feasibility trial of AAV‐mediated FIX gene therapy in low‐ and middle‐income countries aims to demonstrate that gene therapy could become available in resource‐constrained socio‐economic settings. The different strategies for establishing gene therapy provide opportunities for closing the global gap in haemophilia care.